PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2635
https://www.valueinhealthjournal.com/article/S1098-3015(19)35013-2/fulltext
Title :
PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)35013-2&doi=10.1016/j.jval.2019.09.2635
First page :
Section Title :
Open access? :
No
Section Order :
12313